Search Results - "Zeidner, Joshua"

Differentiating the Differentiation Syndrome Associated with IDH Inhibitors in AML by Zeidner, Joshua F

“…Isocitrate dehydrogenase (IDH) inhibitors have clinical activity in acute myeloid leukemia, in part, by differentiating blasts to mature myeloid cells. In the…”
Get full text

Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia by Zeidner, Joshua F, Karp, Judith E

“…Highlights • Alvocidib has been studied in 405 AML patients in a timed sequential regimen (FLAM). • Complete remission rates are 36% in relapsed and refractory…”
Get full text

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML by Sekeres, Mikkael A., Watts, Justin, Radinoff, Atanas, Sangerman, Montserrat Arnan, Cerrano, Marco, Lopez, Patricia Font, Zeidner, Joshua F., Campelo, Maria Diez, Graux, Carlos, Liesveld, Jane, Selleslag, Dominik, Tzvetkov, Nikolay, Fram, Robert J., Zhao, Dan, Bell, Jill, Friedlander, Sharon, Faller, Douglas V., Adès, Lionel

Get full text

TP53 or Not TP53: That Is the Question by Green, Steven D, Zeidner, Joshua F

“…Azacitidine and venetoclax are a standard first-line regimen for patients with newly diagnosed unfit acute myeloid leukemia (AML). In a pooled subset analysis,…”
Get full text

Editorial: Immunotherapy in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) by Jamy, Omer, Zhou, Fuling, Zeidner, Joshua

Get full text

Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia by Rutella, Sergio, Vadakekolathu, Jayakumar, Mazziotta, Francesco, Reeder, Stephen, Yau, Tung-On, Mukhopadhyay, Rupkatha, Dickins, Benjamin, Altmann, Heidi, Kramer, Michael, Knaus, Hanna A, Blazar, Bruce R, Radojcic, Vedran, Zeidner, Joshua F, Arruda, Andrea, Wang, Bofei, Abbas, Hussein A, Minden, Mark D, Tasian, Sarah K, Bornhäuser, Martin, Gojo, Ivana, Luznik, Leo

“…BackgroundImmune exhaustion and senescence are dominant dysfunctional states of effector T cells and major hurdles for the success of cancer immunotherapy. In…”
Get full text

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML by Swords, Ronan T., Coutre, Steven, Maris, Michael B., Zeidner, Joshua F., Foran, James M., Cruz, Jose, Erba, Harry P., Berdeja, Jesus G., Tam, Wayne, Vardhanabhuti, Saran, Pawlikowska-Dobler, Iwona, Faessel, Hélène M., Dash, Ajeeta B., Sedarati, Farhad, Dezube, Bruce J., Faller, Douglas V., Savona, Michael R.

“…Pevonedistat (TAK-924/MLN4924) is a novel inhibitor of NEDD8-activating enzyme (NAE) with single-agent activity in relapsed/refractory acute myeloid leukemia…”
Get full text

Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study by Sallman, David A, Al Malki, Monzr M, Asch, Adam S, Wang, Eunice S, Jurcic, Joseph G, Bradley, Terrence J, Flinn, Ian W, Pollyea, Daniel A, Kambhampati, Suman, Tanaka, Tiffany N, Zeidner, Joshua F, Garcia-Manero, Guillermo, Jeyakumar, Deepa, Komrokji, Rami, Lancet, Jeffrey, Kantarjian, Hagop M, Gu, Lin, Zhang, Yajia, Tan, Anderson, Chao, Mark, O'Hear, Carol, Ramsingh, Giridharan, Lal, Indu, Vyas, Paresh, Daver, Naval G

“…Magrolimab is a monoclonal antibody that blocks cluster of differentiation 47, a don't-eat-me signal overexpressed on cancer cells. Cluster of differentiation…”
Get full text

Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia by Zeidner, Joshua F, Lee, Daniel J, Frattini, Mark, Fine, Gil D, Costas, Judy, Kolibaba, Kathryn, Anthony, Stephen P, Bearss, David, Smith, B Douglas

“…Alvocidib is a cyclin-dependent kinase 9 inhibitor leading to downregulation of the antiapoptotic BCL-2 family member, MCL-1. Alvocidib has shown clinical…”
Get full text

Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy by Hu, Quanyin, Sun, Wujin, Wang, Jinqiang, Ruan, Huitong, Zhang, Xudong, Ye, Yanqi, Shen, Song, Wang, Chao, Lu, Weiyue, Cheng, Ke, Dotti, Gianpietro, Zeidner, Joshua F., Wang, Jun, Gu, Zhen

“…Patients with acute myeloid leukaemia who relapse following therapy have few treatment options and face poor outcomes. Immune checkpoint inhibition, for…”
Get full text

A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure by Zeidan, Amer M, Knaus, Hanna A, Robinson, Tara M, Towlerton, Andrea M H, Warren, Edus H, Zeidner, Joshua F, Blackford, Amanda L, Duffield, Amy S, Rizzieri, David, Frattini, Mark G, Levy, Yair M, Schroeder, Mark A, Ferguson, Anna, Sheldon, Katherine E, DeZern, Amy E, Gojo, Ivana, Gore, Steven D, Streicher, Howard, Luznik, Leo, Smith, B Douglas

“…After failure of hypomethylating agents (HMA), patients with myelodysplastic syndromes (MDS) have dismal survival and no approved treatment options. We…”
Get full text

Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML) by Zeidner, Joshua F, Foster, Matthew C

“…AML patients have an aberrant and dysfunctional immune state, paving the way for novel agents targeting pathways that integrate with immune signaling,…”
Get more information

Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes by Zeidner, Joshua F, Mazerolle, Flora, Norton, Jonathan, Regnault, Antoine, Kristo, Fjoralba, Romero, Heather, Fram, Robert J, Faller, Douglas V, Dalal, Mehul, Ades, Lionel, Sekeres, Mikkael A

Get full text

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results by Daver, Naval G, Vyas, Paresh, Kambhampati, Suman, Al Malki, Monzr M, Larson, Richard A, Asch, Adam S, Mannis, Gabriel, Chai-Ho, Wanxing, Tanaka, Tiffany N, Bradley, Terrence J, Jeyakumar, Deepa, Wang, Eunice S, Sweet, Kendra, Kantarjian, Hagop M, Garcia-Manero, Guillermo, Komrokji, Rami, Xing, Guan, Ramsingh, Giridharan, Renard, Camille, Zeidner, Joshua F, Sallman, David A

“…Magrolimab is a first-in-class humanized monoclonal antibody against cluster of differentiation 47, an antiphagocytic signal used by cancer cells to evade…”
Get full text

Clinical and molecular features of FLT3 juxtamembrane domain missense mutations in acute myeloid leukaemia by Jensen, Christopher E., Montgomery, Nathan D., Galeotti, Jonathan, Foster, Matthew C., Zeidner, Joshua F.

“…FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase involved in regulation of haematopoietic stem cell and progenitor cell proliferation and…”
Get full text

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML by Lachowiez, Curtis A., Ravikumar, Vishvaas I, Othman, Jad, O'Nions, Jenny, Peters, Daniel T, McMahon, Christine, Swords, Ronan, Cook, Rachel, Saultz, Jennifer N., Tyner, Jeffrey W., Dillon, Richard James, Zeidner, Joshua F., Pollyea, Daniel A.

“…The ELN 2024 risk-stratification guidelines for patients with acute myeloid leukemia receiving hypomethylating agents combined with venetoclax were recently…”
Get full text

The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype? by Snow, Anson, Zeidner, Joshua F.

“…Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disorder clinically defined by cytopenias, bone marrow failure, and an increased risk of…”
Get full text

Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy by Knaus, Hanna A, Berglund, Sofia, Hackl, Hubert, Blackford, Amanda L, Zeidner, Joshua F, Montiel-Esparza, Raúl, Mukhopadhyay, Rupkatha, Vanura, Katrina, Blazar, Bruce R, Karp, Judith E, Luznik, Leo, Gojo, Ivana

“…Our understanding of phenotypic and functional signatures of CD8+ T cell dysfunction in acute myeloid leukemia (AML) is limited. Deciphering these deranged T…”
Get full text

Trials and Tribulations of Corrected QT Interval Monitoring in Oncology: Rationale for a Practice-Changing Standardized Approach by Muluneh, Benyam, Richardson, Daniel R, Hicks, Charles, Jensen, Brian C, Zeidner, Joshua F

Get full text

Inversion 16 (inv(16)) acute myeloid leukemia (AML) following treatment with radiation, capecitabine, and temozolomide in a patient with metastatic neuroendocrine tumor (NET) by Joseph, Ranjit, McRee, Autumn J., Mathews, Stephanie, Zeidner, Joshua F.

Get full text